How to take cabergoline for pituitary microadenoma

Patients with pituitary microadenoma need to follow certain medication instructions and precautions when taking cabergoline.

For patients with pituitary microadenoma, the initial dose of cabergoline is usually 0.25mg taken orally twice weekly. This dosage can be adjusted based on the patient's specific condition and the guidance of the physician. While taking cabergoline, doctors will adjust the dose based on the patient's prolactin levels and changes in condition. Generally speaking, each dose adjustment is in increments of 0.25 twice a week for no more than 4 weeks. The maximum dose is usually no more than 1 mg twice weekly.

Cabergoline is absorbed quickly after oral administration, so it is recommended to take it within 1 hour before or after a meal to reduce the irritation of the drug to the gastrointestinal tract. At the same time, patients should try to take their medications on time and not interrupt treatment easily.

To reduce gastrointestinal discomfort caused by the drug, patients can take cabergoline with food.

Patients must strictly follow the doctor's instructions while taking cabergoline and are not allowed to adjust the dosage or change the medication method on their own. Although cabergoline has relatively few side effects, you still need to closely monitor changes in your physical condition. If you experience nausea, vomiting, dizziness and other uncomfortable symptoms, you should report it to your doctor in time. Patients should regularly undergo relevant examinations during the medication period, such as prolactin level testing, pituitary tumor size assessment, etc., in order to understand changes in the condition and drug efficacy in a timely manner.

For women who are preparing to become pregnant or are already pregnant, cabergoline should be used with caution under the guidance of a doctor to prevent adverse effects on the fetus. Cabergoline is contraindicated in those allergic to ergot preparations, those suffering from severe ischemic heart disease and peripheral vascular disease, children under 15 years old, and those with a history of severe mental illness.